Navigation Links
Cepheid Signs Group Purchasing Contract with Novation, the Nation's Largest Healthcare Contracting Organization
Date:5/20/2008

proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and utility, and future market opportunities and market size. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and practices regarding testing levels; customer and market acceptance of the product; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; the fact that VHA, UHC and Provista members have no commitment to purchase any products, and there can be no assurance that they will do so in the future; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ include
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
2. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
3. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
4. Cepheid Reports Fourth Quarter and Full Year 2007 Results
5. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
6. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
9. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
10. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
11. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... NewYork (PRWEB) July 30, 2014 ... the increase of personal health expenditure as well ... health care system, China diagnostic reagent industry has ... occupy over 90%. In 2013, Chinese in vitro ... RMB16.61 billion came from in vitro diagnostic reagents. ...
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
(Date:7/30/2014)... 30, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that their third ... the reduction of recurrence of hypertrophic scars ... initiated. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... AFFiRiS AG announced today that Ali Alloueche is ... This new management position has been established as a ... biopharmaceutical company. As a member of the management team, ... of AFFiRiS AG. Before joining AFFiRiS, Ali Alloueche was ...
... December 2, 2011 Cross reference: ... and can be downloaded free of charge at:   ... report in Science from 2008, Dr. Andrew ... Canada, described how chemicals used as manufacturing additives can ...
... Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) announced today ... balance sheet, removing $31.5 million of liabilities through settlement, ... ) This restructuring reduces the ... the third quarter to $16.5 million. Only about $2.3 ...
Cached Biology Technology:AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited 2AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited 3Eppendorf Video Features Dr Andrew Holt's Work on Bioactive Leachates From Plastic Consumables 2Northwest Bio Implements Major Balance Sheet Clean-Up 2Northwest Bio Implements Major Balance Sheet Clean-Up 3Northwest Bio Implements Major Balance Sheet Clean-Up 4Northwest Bio Implements Major Balance Sheet Clean-Up 5
(Date:7/30/2014)... professor from Wayne State University,s College of Engineering ... Science Foundation for the project, "Nanoparticle-directed synthesis of ... Science Foundation, nanotechnology is the creation and utilization ... properties and functions. A major bottleneck in scaling ... that connect different functional materials into one device. ...
(Date:7/30/2014)... cells types. Researchers would like to understand how to channel ... make up the organs and other structures of living organisms. ... sugars that dangle from proteins on surfaces of cells. , ... has created synthetic molecules that can stand in for the ... the process, they report in the Journal of the ...
(Date:7/29/2014)... University of Bristol,s Nutrition and Behaviour Unit (NBU) has ... when planning meals. , The research, to be presented ... Conference (SSIB 2014) in Seattle, USA this week [29 ... The team was led by Professor Jeff Brunstrom, and ... As part of a Biotechnology and Biological Sciences Research ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... provides insight into mechanisms of evolution , When Mother ... an organism's genome, the duplicated copy is usually deleted, ... genetic redundancy and to preserve biological homeostasis. In ... functional state. Until now, the biological and evolutionary ...
... the University of North Carolina at Chapel Hill have purified ... activity by reversing a molecular modification previously thought permanent. , ... JHDM1A is able to remove a methyl group from histone ... Until just last year, the addition of a methyl group ...
... Hospital of Philadelphia leads a multi-center $6.7 million program ... Mental Health (NIMH) to explore a novel approach to ... and clinical trials in adult patients, the new grant ... immunodeficiency virus: sites on immune cells known as neurokinin-1 ...
Cached Biology News:Fitting in: Newly evolved genes adopt a variety of strategies to remain in the gene pool 2Novel enzyme offers new look at gene regulation 2Federal grant funds research on novel HIV therapy 2Federal grant funds research on novel HIV therapy 3
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
...
...
... The KingFisher magnetic particle based purification ... and DNA/RNA from any sample. They offer ... family comprises three systems- KingFisher, KingFisher mL ... 20 - 1000 l. Each system consists ...
Biology Products: